Evidence map›Paper›PMID 41045719›Full record

ArticlePsychiatry research2025

Do cognitive and neurophysiological effects of acute memantine "challenge" predict its clinical benefits in Alzheimer's Disease?

Neal R Swerdlow, Joyce Sprock, Christopher E Gonzalez, Jenny Min Din, Jessica Minhas, Jo Talledo, Juan L Molina, Yash B Joshi, Gabriel C Léger, Leslie Powell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Neal R SwerdlowDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA. Electronic address: nswerdlow@ucsd.edu.
Joyce SprockDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
Christopher E GonzalezVISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
Jenny Min DinDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jessica MinhasDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jo TalledoDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Juan L MolinaDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
Yash B JoshiDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.
Gabriel C LégerDepartment of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Leslie PowellDepartment of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Brinda RanaMoores Cancer Center, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Lisa Delano-WoodDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VA San Diego Healthcare System, San Diego, CA, USA.
Gregory A LightDepartment of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, CA, USA; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, USA.

Funding

Biomarker Predictors of Memantine Sensitivity in patients with Alzheimer's DiseaseR01AG059640 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2018 to 2022
$2.0M
NIA NIH HHS R01 AG059640
6 · The paper itself

Abstract

"Personalized" interventions based on patients' "biomarkers" may be valuable for treatments that benefit only subsets of patients. The NMDA antagonist, memantine, slows clinical progression of Alzheimer's disease (AD); this effect is heterogeneous in magnitude and duration. This study tested whether acute cognitive or neurophysiological responses to memantine challenge predicted sensitivity to memantine's therapeutic effects. Thirty individuals with mild-to-moderate severity AD (M:F = 13:17) and 24 comparably aged healthy subjects (HCS) (M:F = 12:12) were enrolled. Participants with AD were characterized on 9 experimental measures and their changes after acute memantine "challenge" (20 mg). We then assessed whether acute memantine effects on these measures predicted clinical change over a 24-week open-label trial of memantine. Baseline cognitive (Repeatable Battery for the Assessment of Neuropsychological Status) and neurophysiological measures (prepulse inhibition, P3a latency and auditory steady state response power and coherence) were impaired in participants with AD (p's<0.05-0.0001); neurophysiological deficits were modestly reduced by acute memantine challenge. As a group, participants with AD showed no significant clinical changes across 24 weeks of memantine treatment; subgroups exhibited either small gains or deterioration. With one exception (mismatch negativity latency, p < 0.017), sensitivity of experimental measures to acute memantine challenge did not significantly predict clinical sensitivity to memantine. In summary, a challenge dose design identified neurophysiological measures sensitive to memantine in mild-to-moderate severity AD; acute memantine effects on one measure weakly predicted clinical outcomes over 24 weeks. Impairment in specific measures among participants with AD, and their opposition by memantine, might inform future efforts to identify treatment biomarkers in AD.

Indexed as

Alzheimer’s DiseaseAuditory steady state responseBiomarkerMemantineMismatch negativityPrepulse inhibition

Identifiers

PMID41045719
PMCPMC13263901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.